[The new hemorheologic drug VULM 957 improves cerebral circulation]

The authors investigated the effect of a newly synthetized haemorheological drug VULM 957 for basic haemorheological parameters in vitro and on the cerebral flow in vivo. It was revealed that substance VULM 957 inhibits in a dose-dependent and time-dependent way the platelet aggregation, reduces the viscosity of blood, increases the deformability of red blood cells and increases the cerebral blood flow. Analysis of possible mechanisms of action of VULM 957 indicates that the observed positive haemorheological effects are due to the influence on the fluidity of the platelet and red cell membrane. The increased cerebral blood flow after administration of VULM 957 depends obviously on the reduced viscosity of the blood and the inhibited formation of platelet microaggregates. The presented results justify the assumption that VULM is a perspective substance in the therapy of cerebrovascular diseases.